Saturday, December 13, 2025

Compass Pathways President Steps Down To An Advisory Role

Compass Pathways (Nasdaq: CMPS) announced this morning major changes to its executive team. One of its co-founders, President and Chief Business Officer Lars Wilde is stepping down to take a senior advisory role.

“We have built an amazing company at COMPASS and I am grateful to everyone who continues to support us,” Wilde said in a statement. “This is a natural time for me to transition to an advisory role and I am proud to be able to continue working with COMPASS.”

The move is effective as of January 1, 2022.

Wilde is said to have been integral to the company’s strategic and operational efforts, “including fundraising, business development, and the development of its Discovery Center.”

The firm also announced Matthew Owens as its General Counsel and Chief Legal Officer starting February 1, 2022, while Mike Falvey was announced as the incoming CFO earlier this month.

Compass Pathways last traded at US$23.73 on the Nasdaq.


Information for this briefing was found via Edgar and Compass Pathways. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Guanajuato Silver: Q3 Results Overshadowed By Silver Ripping

I Went to See the Highest Grade Silver on Earth | Nord Precious Metals

Recommended

Steadright Locks Up Goundafa Polymetallic Mine Under Binding MOU

Emerita Resources Awards Contract For Pre-Feasibility Study On Iberian Belt West Project

Related News

David Nutt: Amanita Muscaria Due For More Research – The Daily Dive

Today on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt,...

Wednesday, March 10, 2021, 01:30:00 PM

Compass Pathways, Psilocybin Research Firm, Files For Nasdaq IPO

It appears that some authenticity and validation might be coming to the psychedelics space. Compass...

Saturday, August 29, 2020, 11:43:00 AM

Compass Pathways Granted Its Tenth Overall Patent Related To Psilocybin

Compass Pathways (NASDAQ: CMPS) this morning issued a brief release, indicating it has been granted...

Tuesday, November 23, 2021, 07:55:20 AM

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

Compass Pathways Sees “Reduction In Depressive Symptom” In Phase IIb Psilocybin Clinical Trial

Compass Pathways (Nasdaq: CMPS) announced today that its phase IIb clinical trial of COMP360 psilocybin therapy...

Tuesday, November 9, 2021, 12:33:00 PM